GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Videos|April 28, 2020
Mental Health Issues When College Students Are Sent Home by COVID-19
Author(s)John F. Greden, MD
Dr John Greden discusses many issues around college mental health and the upheaval the COVID-19 pandemic is causing in this population.
Advertisement
Dr John Greden discusses many issues around college mental health and the upheaval the COVID-19 pandemic is causing in this population.
Dr Greden is Executive Director,
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5